

**INFORMATION DISCLOSURE  
CITATION**

(Use several sheets if necessary)

Atty. Docket No.

**4865-103**

Applicant

**GIANNINI et al.**


Filing Date

**January 5, 2006**

Serial No.

**10/563,480**

TC/A.U.

**1626**
**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

						TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		YES	NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Griggs et al, "Inhibition of Proliferative Retinopathy ...", American Journal of Pathology, Vol. 160, No. 3, March 2002.
	Cirla et al, "Combretastatins: from natural products to drug discovery", Nat. Prod. Rep., 2003, <b>20</b> , 558-564.
	Nambu et al, "Combretastatin A-4 Phosphate Suppresses Development ...", Investigative Ophthalmology & Visual Science, August 2003, Vol. 44, No. 8.
	Nabha et al, "Combretastatin A-4 Prodrug Induces Mitotic ...", Clinical Cancer Research, Vol. 8, 2735-2741, August 2002.
	Griggs et al, "Combretastatin-A4 Disrupts Neovascular Development ...", British Journal of Cancer (2001) <b>84</b> (6), 832-835.
	Nabha et al, "Preclinical Report Evaluation of Combretastatin A-4 prodrug in a non-Hodgkin's ...", Anti-Cancer Drugs, 2001, <b>12</b> , pp. 57-63.

\*Examiner

/Rei Tsang Shiao/

Date Considered

4/14/09

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /R.S./

1428736